Study S002789

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GZR18 Injection in Healthy Subjects Following Single Dose and Once-weekly Dose for 2 Consecutive Weeks Until Reaching the Target Dose

ClinicalTrials.gov record

Registration

Registration: NCT06548997
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 57
Start: 2021-12-02
Primary completion: 2022-10-20
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Type 2 Diabetes; Overweight and Obesity
Interventions: DRUG:GZR18; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

TEAE [after 28/35 days of treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.